Abstract: Embodiments of the present disclosure provide a method and system for training a model by using training data. The training data includes a plurality of samples, each sample includes N features, and features in the plurality of samples form N feature columns, and the method includes: determining an importance value of each of the N feature columns; determining whether the importance value of each of the N feature columns satisfies a threshold condition; performing a dimension reduction on M feature columns to generate P feature columns in response to the determination that the importance values of the M feature columns do not satisfy the threshold condition, wherein M<N and P<M; merging (N?M) feature columns having importance values that satisfy the threshold condition and the generated P feature columns to obtain (N?M+P) feature columns; and training the model based on the training data including the (N?M+P) feature columns.

Abstract: The present disclosure provides compounds represented by Formula I or Formula VIII: wherein R1a, R1b, M, A, E, QA, and QB are as defined in the specification, and the salts and solvates thereof. Compounds of Formula I are degraders of STAT3 or degraders of STAT3 and STAT1. Compounds of Formula VIII are inhibitors of STAT3. STAT3 degraders and inhibitors are useful for the treatment of cancer and other diseases.

Abstract: The present disclosure provides fused 1,4-oxazepines and related analogs represented by Formula (I) and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R1, R2a, R2b, R3a, R3b, R4, R5, A, and Y are as defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula (I) to treat a condition or disorder responsive to inhibition of BET bromodomains such as cancer.

Abstract: The present disclosure provides compounds represented by Formula I-A: A1-L1-B1??I-A and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein A1, B1, and L1 are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I-A for use to treat a condition or disorder responsive to degradation of MDM2 protein such as cancer.

Abstract: Provided are compounds represented by Formula IA: (IA), and the pharmaceutically acceptable salts and solvates thereof, wherein R, R1a, R1b, L1, L2, L3, X, A, B and C are as defined as set forth in the specification. Also provided compounds of Formula IA for use to treat a condition or disorder responsive to Mcl-1 inhibition such as cancer.

Abstract: The present disclosure provides compounds represented by Formula I: wherein R2a, R2b, R2c, R2d, R3, R13, and Z are as defined in the specification, and the salts and solvates thereof. Compounds of Formula I are cereblon (CRBN) ubiquitination inhibitors or monofunctional synthetic intermediates that can be used to prepare PROTAC molecules. CRBN ubiquitination inhibitors and PROTAC molecules are useful for the treatment of cancer and other diseases.

Abstract: The present disclosure provides compounds represented by Formula (I) and the salts or solvates thereof, wherein R3a, E, L, A1, B1, X1, X2, Z1, and Z2 are as defined in the specification. Compounds having Formula (I) are androgen receptor degraders useful for the treatment of cancer and other diseases.

Abstract: Provided are compounds represented by Formula (I-A) and the pharmaceutically acceptable salts and solvates thereof, wherein R8, R9a, R9b, R9c, R9d, X, Y, Z, Z1, W, and (aa) are as defined as set forth in the specification. Provided are also compounds of Formula (I-A) for use to treat a condition or disorder responsive to Mcl-1 inhibition such as cancer.

Abstract: The present disclosure provides compounds represented by Formula I: I, and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R1, R2a, R2b, R3, R4, Ar, L, X, Y, and B are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I for use to treat a condition or disorder responsive to degradation of BET bromodomains such as cancer.

Abstract: Disclosed is compound of formula I and the pharmaceutically acceptable salts and solvates thereof, wherein R, R1a, R1b, R1h, L2, L3, #, #, # are as defined as set forth in the re) specification. Disclosed is compound of formula I for use to treat a condition or disorder responsive to Mcl-1 inhibition such as cancer.

Abstract: The present disclosure provides compounds represented by Formula I and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R1, R2a, R2b, R3a, R3b, R4, Ar, L, X, Y, and B are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I for use to treat a condition or disorder responsive to degradation of BET bromodomains such as cancer.

Abstract: The present disclosure provides compounds represented by Formula I: wherein R1, R2, R3, and R4 are as defined in the specification, and the salts and solvates thereof. Compounds of Formula I are EED inhibitors. EED inhibitors are useful for the treatment of cancer and other diseases.

Abstract: The present disclosure provides compounds represented by Formulae I and IV: wherein R1a, R1b, R2a, R2b, A, E, QD, and QE are as defined in the specification, and the salts and solvates thereof. Compounds of Formula I are degraders of STAT3. Compounds of Formula IV are inhibitors of STAT3. STAT3 degraders and inhibitors are useful for the treatment of cancer and other diseases.

Abstract: A novel synthetic uniform circular array (SUCA) method for generating vortex electromagnetic (EM) wave carrying high orbital angular momentum (OAM) mode has the following steps. N antenna elements are placed radially to form a uniform circular array (UCA), where N is a positive integer. By rotating the array elements to various spatial locations, modifying their feeding phases, and superimposing the generated fields at various spatial locations, SUCA can beat the limit of space and configure more array elements to generate vortex electromagnetic (EM) waves carrying high mode OAMs. Meanwhile, due to the more synthetic array elements and smaller aperture than the traditional UCA, the purity of OAM mode is higher and it is more flexible to adjust the main lobe directions of these vortex waves carrying different OAM modes, and can generate vortex EM waves.

Abstract: A novel synthetic uniform circular array (SUCA) method for generating vortex electromagnetic (EM) wave carrying high orbital angular momentum (OAM) mode has the following steps. N antenna elements are placed radially to form a uniform circular array (UCA), where N is a positive integer. By rotating the array elements to various spatial locations, modifying their feeding phases, and superimposing the generated fields at various spatial locations, SUCA can beat the limit of space and configure more array elements to generate vortex electromagnetic (EM) waves carrying high mode OAMs. Meanwhile, due to the more synthetic array elements and smaller aperture than the traditional UCA, the purity of OAM mode is higher and it is more flexible to adjust the main lobe directions of these vortex waves carrying different OAM modes, and can generate vortex EM waves.

Abstract: The present disclosure provides compounds represented by Formula (I): A-L-B (I), and the salts or solvates thereof, wherein A, L, and B are as defined in the specification. Compounds having Formula (I) are androgen receptor degraders useful for the treatment of cancer.

Abstract: The present disclosure provides compounds represented by Formula (I): A-L-B and the salts or solvates thereof, wherein A, L, and B are as defined in the specification. Compounds having Formula I are estrogen receptor degraders useful for the treatment of cancer.

Abstract: Methods and apparatuses for training model based on random forest are provided. The method includes: dividing worker nodes into one or more groups; performing random sampling, by worker nodes in each group, in the preset sample data to obtain the target sample data; and training, by the worker nodes in each group, one or more decision tree objects using the target sample data. Example embodiments of the present disclosure do not need to scan the complete sample data for once, thereby greatly reducing the amount of data to be read, the time cost, and further the iterative update time of the model. The efficiency of training is improved.

Abstract: The present disclosure provides compounds represented by Formula (I): Formula (I) and the pharmaceutically acceptable salts and solvates thereof, wherein R1, R2a, R2b, R3a, R3b, R4, Y, ?, Ar, W, L, and B are as defined as set forth in the specification. The present disclosure also provides compounds of Formula (I)I for use to treat a condition or disorder responsive to inhibition and/or degradation of BET bromodomains such as cancer.

Abstract: The present disclosure provides compounds represented by Formula I-A: A1-L1-B1 I-A and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein A1, B1, and L1 are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I-A for use to treat a condition or disorder responsive to degradation of MDM2 protein such as cancer.